Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3952
Gene Symbol: LEP
LEP
0.010 AlteredExpression disease BEFREE BMI and MRI intra-abdominal fat significantly differed among these three groups, whereas DXA total fat mass and leptin levels were higher in the OND group, but did not differ between HC and FPLD2. 30165155 2019
Entrez Id: 9452
Gene Symbol: ITM2A
ITM2A
0.010 Biomarker disease BEFREE This suggests that targeting of Itm2a or its related pathways, including autophagy, may have potential as a therapy for FPLD2. 28872940 2017
Entrez Id: 50964
Gene Symbol: SOST
SOST
0.010 Biomarker disease BEFREE Patients with lipoatrophic diabetes (BSCL) have high serum concentrations of sclerostin, normal or high BMD, and reasonable trabecular bone mass measured by TBS. 28390904 2017
Entrez Id: 1803
Gene Symbol: DPP4
DPP4
0.010 AlteredExpression disease BEFREE On the other hand, patients with FPLD2 presented significant higher levels of insulin (median 11.2 vs 5.3; p = 0.015), triglycerides (184.9 ± 75.4 vs 89.1 ± 51.0; p < 0.01) and DPP4 (4.89 ± 0.92 vs 3.93 ± 1.08; p = 0.04). 28450900 2017
Entrez Id: 4023
Gene Symbol: LPL
LPL
0.010 Biomarker disease BEFREE The expression of PPARG2, RB1, CCND3 and LPL in thigh but not in abdomen scAT was significantly reduced (67%, 25%, 38% and 66% respectively) in patients with FPLD2. 18805829 2009
Entrez Id: 896
Gene Symbol: CCND3
CCND3
0.010 Biomarker disease BEFREE The expression of PPARG2, RB1, CCND3 and LPL in thigh but not in abdomen scAT was significantly reduced (67%, 25%, 38% and 66% respectively) in patients with FPLD2. 18805829 2009
Entrez Id: 3172
Gene Symbol: HNF4A
HNF4A
0.010 GeneticVariation disease BEFREE Concerning the Gly15Gly polymorphism, the TT genotype was found in 275 subjects (79.9%), the TG genotype in 67 subjects (19.5%) and the GG genotype in 2 subjects (0.6%): one with maturity onset diabetes of young age (MODY-diabetes) and one with Lipoatrophic Diabetes Syndrome (LPDS). 11029602 2000
Entrez Id: 3643
Gene Symbol: INSR
INSR
0.020 GeneticVariation disease BEFREE Overall, these results provide the first clear evidence against the involvement of the IR gene in the pathogenesis of any clinical form of LD. 7829633 1995
Entrez Id: 3643
Gene Symbol: INSR
INSR
0.020 GeneticVariation disease BEFREE Altered expression and function of the insulin receptor in a family with lipoatrophic diabetes. 2903867 1988
Entrez Id: 10269
Gene Symbol: ZMPSTE24
ZMPSTE24
0.200 Biomarker disease MGD
Entrez Id: 208
Gene Symbol: AKT2
AKT2
0.300 Biomarker disease CTD_human Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. 19793595 2009
Entrez Id: 857
Gene Symbol: CAV1
CAV1
0.300 Biomarker disease CTD_human Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. 19793595 2009
Entrez Id: 3991
Gene Symbol: LIPE
LIPE
0.300 Biomarker disease CTD_human
Entrez Id: 63924
Gene Symbol: CIDEC
CIDEC
0.300 Biomarker disease CTD_human
Entrez Id: 5346
Gene Symbol: PLIN1
PLIN1
0.300 Biomarker disease CTD_human
Entrez Id: 5468
Gene Symbol: PPARG
PPARG
0.520 Biomarker disease CTD_human Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy. 19793595 2009
Entrez Id: 5468
Gene Symbol: PPARG
PPARG
0.520 AlteredExpression disease BEFREE The expression of PPARG2, RB1, CCND3 and LPL in thigh but not in abdomen scAT was significantly reduced (67%, 25%, 38% and 66% respectively) in patients with FPLD2. 18805829 2009
Entrez Id: 5468
Gene Symbol: PPARG
PPARG
0.520 GeneticVariation disease BEFREE Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal proliferator-activated receptor-gamma. 16412238 2006
Entrez Id: 5468
Gene Symbol: PPARG
PPARG
0.520 Biomarker disease MGD
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.800 GeneticVariation disease BEFREE A human induced pluripotent stem cell (iPSC) line was generated from peripheral blood mononuclear cells (PBMCs) of a 30 year-old male patient with FPLD2 who had a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene using non-integrating episomal vector technique. 31794942 2020
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.800 Biomarker disease BEFREE LMNA-associated familial partial lipodystrophy (FPLD2) comprises insulin resistance, muscle hypertrophy and lipoatrophy. 30165155 2019
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.800 GeneticVariation disease BEFREE To evaluate the phenotypic heterogeneity and glucocorticoid sensitivity in FPLD2 patients exhibiting the p.R482W or p.R644C LMNA mutations. 30954027 2019
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.800 GeneticVariation disease BEFREE In patients with unexplained pancreatitis and hypertriglyceridemia, lipodystrophies such as familial partial lipodystrophy type 2 (FPLD2; Dunnigan type, due to LMNA mutations) should be considered. 30296183 2019
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.800 Biomarker disease BEFREE In agreement with these in vitro results indicating conversion of FPLD2 brown preadipocytes toward the white lineage, adipose tissue from FPLD2 patient neck, an area of brown adipogenesis, showed a white phenotype reminiscent of its brown origin. 31375660 2019
Entrez Id: 4000
Gene Symbol: LMNA
LMNA
0.800 GeneticVariation disease BEFREE Familial partial lipodystrophy type 2 (FPLD2) is caused by an autosomal dominant mutation in the LMNA gene. 29108996 2018